Related Experiment Videos
Gene therapy approaches for the selective killing of cancer cells
Eva Maria Westphal1, Harald von Melchner Hv
1Laboratory for Molecular Hematology, University of Frankfurt Medical School, Theodor-Stern-Kai 7, Frankfurt am Main, 60590, Germany.
Abstract:
This review describes gene therapy strategies that take advantage of defective signal transduction pathways to selectively kill cancer cells without adversely affecting normal cells. The distinctive features of cancer cells currently exploited by gene therapy include mitosis, cell permissiveness to infection, specific protease activity, and the activity of the p53, Rb/E2F and wnt/catenin signal transduction pathways. In most cases, proof of concept has been obtained in vitro and in vivo, but only a few approaches made it to the clinic. Overall, the clinical success rate has been disappointing and it is concluded that the gene therapy of cancer requires more innovation and hard work before its potential can be fully realized.
Insights
Gene therapy uses cancer cell defects to selectively kill tumors. While promising, clinical success for cancer gene therapy remains limited, requiring further innovation.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Gene therapy offers a promising avenue for cancer treatment by targeting cancer-specific vulnerabilities.
- Defective cellular pathways in cancer cells present unique targets for selective therapeutic intervention.
Purpose of the Study:
- To review current gene therapy strategies for cancer that exploit cancer-specific defects.
- To evaluate the progress and limitations of these strategies from preclinical studies to clinical application.
Main Methods:
- Review of scientific literature on gene therapy for cancer.
- Analysis of strategies targeting cancer cell mitosis, permissiveness to infection, protease activity, and specific signal transduction pathways (p53, Rb/E2F, wnt/catenin).
- Assessment of in vitro and in vivo proof-of-concept studies and clinical trial outcomes.
Main Results:
- Several gene therapy strategies leverage distinct cancer cell features for selective killing.
- Proof of concept is established for many approaches in preclinical models.
- Limited clinical translation and disappointing success rates have been observed.
Conclusions:
- Gene therapy for cancer holds significant potential but faces challenges in clinical efficacy.
- Further innovation and dedicated research are essential to realize the full potential of cancer gene therapy.